Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
The Company's product candidate, MPC-150-IM, is in Phase III trials for the treatment of both advanced and end-stage chronic heart failure (CHF). MPC-150-IM consists of approximately 150 million MPCs administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within damaged tissue. The Company is developing its product candidate, MPC-06-ID, for the treatment of chronic low back pain (CLBP). MPC-06-ID is its Phase III product candidate. MPC-06-ID consists of a unit dose of approximately six million MPCs. It is injected by syringe directly into a targeted damaged disc in an outpatient procedure. MSC-100-IV is its Phase III intravenously delivered product candidate, which is being developed for the treatment of acute Graft Versus Host Disease (aGVHD) following allogeneic bone marrow transplantation. MPC-300-IV is an intravenously delivered immunomodulatory product candidate for the treatment of chronic inflammatory conditions, including biologic-refractory rheumatoid arthritis and diabetic nephropathy. The Company has conducted Phase II trial of MPC-300-IV in patients with biologic-refractory rheumatoid arthritis. It focuses on Phase III development for biologic-refractory rheumatoid arthritis.
The Company is developing MPC-25-Osteo for spinal fusion. MPC-25-Osteo is a Phase III-ready product candidate. All doses of MPC-25-Osteo for the treatment of spinal fusion consists of approximately 25 million MPCs delivered on a collagen ceramic carrier material into the disc space with stabilizing hardware. MPC-25-IC is the Company's Phase II product candidate for the treatment of acute myocardial infarction. The Company is developing MPC-300-IV for the treatment of diabetic complications, including diabetic kidney disease known as diabetic nephropathy. The Company is also developing MSC-100-IV for the treatment of Crohn's disease refractory to steroids and immune suppressants. It is evaluating MPC-CBE to expand hematopoietic precursors from cord blood for transplantation in hematological cancer patients.
L 38 55 Collins St
The company trades on NASDAQ exchange. The company headquarter is located in Australia. The company was established in the 2004.| Ticker | MESO |
| Long Name | Mesoblast Limited |
| Short Name | Mesoblast |